PUBLICATIONS > CADTH Symposium 2023
16 May 2023
CADTH Symposium 2023: PERSONALIZE MY TREATMENT (PMT): A CANADIAN CANCER PATIENT REGISTRY
PERSONALIZE MY TREATMENT (PMT): A CANADIAN CANCER PATIENT REGISTRY
Maud Marques,1 Karen Gambaro,1Rosa Garyfallia Christodoulopoulos,1 Ethan Hoang,1 Suzan McNamara,1 the Exactis Network, Gerald Batist,1,2 and Kostas Trakas1
1Canadian National Centers of Excellence – Exactis Innovation, Montreal, Qc, Canada;
2Segal Cancer Centre-Jewish General Hospital, Montreal, Qc, Canada.
Cancer patient registries, and associated clinical data collection, represent an emerging trend to understand the impact of disease on the population, identify contributing factors, and assess disparities in cancer incidence and outcome. In addition, longitudinal clinical data collection enhances the understanding of patterns of care. Exactis Innovation (Exactis) is a Canadian not-for-profit Business-Led National Centers of Excellence organization. Exactis has established a unique standardized digital cancer patient registry called “Personalize My Treatment” (PMT) active at 15 hospital sites across 5 Canadian provinces.
Exactis has executed agreements with the hospital sites within its network that permit on-site dedicated PMT Coordinators to enroll patients in PMT and to collect longitudinal real-world data (RWD) in a standardized secured de-identified online database. Access to digitalized pathology, images, biospecimens, and information from patient’s medical records can be collected retrospectively or prospectively for research purposes.
To date, PMT has over 8,400 participants enrolled. The main cancer cohorts enrolled are breast, colorectal, lung, prostate, melanoma, and ovarian. Information collected includes demographics, cancer type and history, events of progression/recurrence, diagnosis, tumour resection, treatment sequences, and molecular profile’s results.
Exactis has established a pan-Canadian network and a cancer patient registry able to provide the capacity and a tremendous resource for RWD analysis, that reflects the full diversity of Canadian oncology patients. The Exactis’ network can be leveraged to bring a higher level of certainty on the clinical benefits of new agents in a real-world population, as well as to support new indications and highlight treatment gaps.